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Introduction: Cell adhesion molecules (CAM) are required for maintaining a normal 
epithelial phenotype, and abnormalities in CAM expression have been related to can-
cer progression, including bladder urothelial carcinomas. There is only one study that 
correlates E-cadherin and α-, β- and γ-catenin expression with prognosis of upper tract 
urothelial carcinomas. Our aim is to study the pattern of immune expression of these 
CAMs in urothelial carcinomas from the renal pelvis and ureter in patients who have 
been treated surgically. Our goal is to correlate these expression levels and characteris-
tics with well-known prognostic parameters for disease-free survival.
Materials and Methods: We evaluated specimens from 20 patients with urothelial car-
cinomas of the renal pelvis and ureter who were treated with nephroureterectomy or 
ureterectomy between June 1997 and January 2007. CAM expression was evaluated 
by immunohistochemistry in a tissue microarray and correlated with histopathological 
characteristics and patient outcomes after a mean follow-up of 55 months.
Results: We observed a relationship between E-cadherin expression and disease re-
currence. Disease recurrence occurred in 87.5% of patients with strong E-cadherin 
expression. Only 50.0% of patients with moderate expression and 0% of patients with 
weak or no expression of E-cadherin had disease recurrence (p = 0.014). There was also 
a difference in disease-free survival. Patients with strong E-cadherin expression had a 
mean disease-free survival rate of 49.1 months, compared to 83.9 months for patients 
with moderate expression (p = 0.011). Additionally, an absence of α-catenin expression 
was associated with tumors that were larger than 3 cm (p = 0.003).
Conclusions: We demonstrated for the first time that immune expression of E-cadhe-
rin is related to tumor recurrence and disease-free survival rates, and the absence of 
α-catenin expression is related to tumor size in upper tract urothelial carcinomas.
INTRODUcTION
Upper tract urothelial carcinomas (UUC) 
are defined as tumors that occur in the renal pel-
vis and ureter, and these carcinomas represent 5 
to 8% of all patients with urothelial cancers (1). 
Additionally, these carcinomas have been asso-
ciated with aggressive behavior. Previous studies 
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have suggested that the thin sub-epithelial con-
nective tissue and muscularis propria of the up-
per urinary tract are responsible for early tumor 
invasion. Furthermore, diagnosis of this carci-
noma tends to be delayed because of a lack of 
symptoms and a lack of neoplastic cells in urine 
cytology (2,3).
 There are few predictors of tumor re-
currence after nephroureterectomy. The main 
prognostic factors are the patient’s age, tumor 
location, and tumor architecture, stage and his-
tological grade. However, there is currently no 
evidence that specific tumor characteristics would 
be able to define patients that could benefit from 
adjuvant treatment (4).
 Biomarkers have not been extensively 
studied in UUCs. P53 mutations (5) and angio-
genesis (6), which are well-known markers of 
worse prognosis in patients with bladder UCs, 
have also been related to worse prognosis in pa-
tients with UUCs.
 E-cadherin is a transmembrane glyco-
protein that mediates the selective adhesion of 
epithelial cells. This protein is required for in-
teractions and maintenance of tissue integrity 
(7). α-Catenin mediates interactions between the 
E-cadherin/β-catenin complex and the actin cy-
toskeleton (8), whereas γ-catenin probably has a 
role on desmosomal plaques (9).
 The role of adhesion molecules in UC is 
still controversial, and only a few studies have 
been published in the literature on this topic 
(6,10). Dysfunctions in cell-cell adhesion mole-
cules have been related to the initial steps of tu-
mor invasion and the development of metastasis 
in urothelial bladder carcinomas. Recently, Kashi-
buchi et al. (11) demonstrated aberrant expression 
of E-cadherin and α-, β- and γ-catenin in 40 to 
50% of urothelial bladder carcinoma cases. They 
also related aberrant expression to tumor stage 
and cancer specific survival.
 The aim of our study is to evaluate the 
expression of the E-cadherin and α-, β- and 
γ-catenin adhesion molecules in UUC cells by 
immunohistochemistry using a tissue microarray 
construction (TMA) of specimens from 20 patients 
who underwent ureterectomy or nephroureterec-
tomy for treatment of their UUCs.
MATERIALS AND METHODS
Patients
 We retrospectively evaluated surgical 
specimens from 20 patients with UUC who un-
derwent nephroureterectomy or ureterectomy 
performed by a single surgeon (MS) from 1997 
to 2007. The median age of the patients was 67 
years old. Twelve patients had tumors of the re-
nal pelvis, five had tumors of the ureter, and 
three had multifocal tumors that were present 
in both the renal pelvis and the ureter. Clinical 
and pathological characteristics of the patients 
are listed in Table-1.
 All subjects provided informed consent 
before participating in the study, and the study 
was approved by the Institutional Board of Ethics 
(#0720/09).
 The specimens were fixed in buffered 10% 
formalin, routinely processed, stained with hema-
toxylin and eosin, and examined by a single pa-
thologist (KRML). The prognostic factors that were 
evaluated included tumor grade, which was deter-
mined according to the 2004 WHO classification 
tumor stage (TNM 2010), tumor size, multicentric-
ity and neoplastic microvascular invasion. The 
pattern and intensity of immunoexpression of the 
adhesion molecules were compared to the above 
prognostic factors and with the disease-free sur-
vival rates after a mean follow-up of 55 months.
TMA construction
TMA construction was performed as previ-
ously described (12). Slides that contained each of 
the patients’ tumors were selected by examining 
areas that best represented the entire tumor. Two 
areas from each tumor were marked with perma-
nent ink to correspond to areas included in TMA 
analysis. A 1.0 mm punch was used.
 To create the slides, a three-micrometer 
section from the paraffin block was placed onto 
an adhesive-coated slide. During the heat antigen 
retrieval process, slides were placed in a citrate 
buffer (1 mM, pH 6.0) and heated for 30 min in 
a steamer. Then, slides were incubated overnight 
at 4ºC with a 1:50 dilution of monoclonal anti-
bodies against E-cadherin (Dako Cytomation, CA, 
USA) and β-catenin (BD San Jose, CA, USA). A 
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Table 1 - Patients characteristics.
Patients(n = 20)
Age (years)
Mean 66,5
Min - Max 52-85
Gender
Female 4 (20%)
Male 16 (80%)
Pathological Stage
pTa-pT1 7 (35%)
pT2-pT3 13 (65%)
Tumor size
≤ 3 cm 6 (30%)
>3 cm 14 (70%)
Tumor multicentricity
Yes 5 (25%)
No 15 (75%)
Tumor Grade
High 15 (75%)
Low 5 (25%)
Microvascular Invasion
Yes 10 (50%)
No 10 (50%)
Recurrence
Yes 10 (50%)
No 10 (50%)
1:100 dilution of antibodies against γ-catenin 
(Zymed Montrouge, France) and α-catenin (Santa 
Cruz, St Cruz, CA, USA) was used. The LSAB sys-
tem was used for immunostaining (LSAB; Dako 
Cytomation, CA, USA). Color was developed by 
reactions with a 3.3’-diaminobenzidine substrate-
chromogen solution followed by counterstaining 
with Harris hematoxylin. Finally, slides were de-
hydrated, coverslipped, and examined under light 
microscope.
 The expression of each marker was evalu-
ated by a single pathologist (KRML). Semi-quan-
titative analysis was performed for all antibodies 
according to the intensity of staining: negative, 
weak, moderate and strong (Figure-1).
Statistical Analysis
 Statistical analyses were performed using 
SPSS 16.0 for Windows (release 16.02). For com-
parison between categories, we used an ANOVA and 
Student’s t-tests and significance was determined 
at p ≤ 0.05. For adhesion molecule expression pro-
files with significant associations with recurrence 
risks, Kaplan-Meier survival curves were used to 
illustrate disease-free survival. We performed a 
log-rank test to show differences between curves.
RESULTS
 All cases were usual urothelial carci-
nomas without any other specification. Fifteen 
(75%) cases were high grade urothelial carci-
nomas. Only two (10%) cases were staged pTa, 
A
c
B
D
Figure 1 - Examples of the subjective analysis of the intensity 
of immune expression that was considered as negative (A), 
weak (B), moderate (c) and strong (D).
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five (25%) were pT1, three (15%) pT2 and the 
remaining 10 (50%) were staged pT3.
 The pattern of staining was membrane 
for E-chaderin and cytoplasmatic for the other 
markers. Moderate and strong E-cadherin ex-
pression was significantly related to tumor re-
currence (p = 0.014) (Figure-2), while moderate 
γ-catenin expression was correlated with a lower 
disease-free survival rate with marginal statisti-
cal significance (p = 0.071)(Table-2). There was 
no relationship between β-catenin or α-Catenin 
expression with tumor recurrence, p = 0.999 and 
p = 0.465 respectively.
 When CAM expression was analyzed in 
relation to the classical prognostic parameters 
of pathological stage, tumor grade, microvascu-
lar invasion, multicentricity and tumor size, we 
found that α-catenin expression was negative or 
weak in 92.9% of tumors that were larger than 3 
cm (p = 0.003) (Table-2).
DIScUSSION
 When studying immune expression of 
E-cadherin and α-, β-, γ-catenin in UUC cells, 
we were able to show that moderate or strong 
 Kaplan-Meier curves showed that pa-
tients with strong E-cadherin expression had a 
mean disease-free survival rate of 49.1 months. 
Patients with moderate expression levels had a 
mean survival of 83.9 months (p = 0.011) (Fig-
ure-3). γ-catenin, β-Catenin and α-Catenin ex-
pression levels did not demonstrate differences 
in disease-free survival length, p = 0.053; p = 
0.951; p = 0.913, respectively.
Figure 2 - Micrography of an IHc reaction showing strong expression of E-cadherin.
expression levels of E-cadherin were related 
with both tumor recurrence (p = 0.014) and a 
shorter time before tumor recurrence (p = 0.011). 
Additionally, negative or weak expression of 
α-catenin were correlated with larger tumors 
(p = 0.003). This is the first study reporting on 
the relationship between immune expression of 
members of the cadherin-catenin complex and 
UUC prognosis.
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E-cadherin and γ-catenin were moder-
ately or strongly expressed in most patients, but 
α-catenin was absent or lost in the majority of 
cases.
 Cadherins represent a family of trans-
membrane glycoproteins that mediate homo-
phile, calcium-dependent, intercellular adhe-
sion. E-cadherin is the major cadherin molecule 
expressed by epithelial cells. Linkage between 
E-cadherin and intracellular catenins is neces-
sary for the formation of strong intercellular 
adhesion. β-catenin and γ-catenin bind directly 
to the cytoplasmic domain of E-cadherin, and 
α-catenin links the bound β-catenin to actin in 
the cytoskeleton (13,14).
 Several studies have explored the ex-
pression of cadherins and catenins and their role 
as prognostic factors in urothelial bladder car-
cinomas. These studies suggested that aberrant 
expression of α-catenin, β-catenin, E-cadherin 
and γ-catenin correlates with higher tumor stag-
es and worse patient prognosis (15-17). Kashibu-
chi et al. showed a correlation between aberrant 
β-catenin and γ-catenin expression with tumor 
stage and a correlation between γ-catenin with 
tumor grade in urothelial bladder carcinomas. 
Furthermore, they found that abnormal expres-
sion of E-cadherin was an independent predic-
tor of disease-specific survival in this neoplasia 
(11). Different from them, we tried to add details 
to the pattern of immune expression, stratifying 
the intensity of staining in weak, moderate and 
strong patterns. The subjective quantification 
should be better explored in future studies by 
evaluating adhesion molecules gene expression 
profiles using quantitative real time PCR that 
could be proposed as markers to diagnose or fol-
low patients that harbor upper urinary tract uro-
thelial carcinomas.
 In our study, we found an association be-
tween overexpression of E-cadherin and tumor 
recurrence. These data contradict previous stud-
ies that have demonstrated that loss of E-cad-
herin is related to higher tumor stages and worse 
prognosis behavior in many cancers, including 
bladder tumors. In studies that specifically ex-
amined UUCs, Velickovic et al. showed that, in 
sporadic urothelial carcinomas and in patients 
Figure 3 - Kaplan-Meier curve for recurrence-free survival according to E-cadherin expression (p=0.011). 
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with Balkan endemic nephropathy, lower E-cad-
herin expression was correlated with higher tu-
mor stages in both groups (18). However, some 
authors postulate that E-cadherin expression 
can be reversibly controlled by methylation (19). 
This methylation would be responsible for E-
cadherin down-regulation during the epithelial-
mesenchymal transition, which is an important 
stage in tumor invasion and dissemination (20). 
But for tumor establishment in the metastatic 
site there is a requirement for E-cadherin re-ex-
pression (21). In our study, we observed re-ex-
pression of E-cadherin that was more expressed 
in pT3 local tumors (69.3%) and that were able 
to disseminate or recur locally. Interestingly, in 
agreement with our data, a recent study pub-
lished by Lim et al. (22) found normal expression 
of E-cadherin in both usual and micropapillary 
urothelial bladder carcinomas, and that was in-
dependent of tumor stage, tumor grade or pres-
ence of microvascular invasion. In their study, 
they proposed that loss of E-cadherin expression 
may be a characteristic of a histologically spe-
cial plasmocytoid or signed ring cell urothelial 
carcinoma.
 Our study also showed that lower expres-
sion of α-catenin was associated with tumors 
larger than 3 cm (p = 0.003). Tumor size is a 
very important prognostic parameter in UC. It is 
related to tumor recurrence, with 7-fold increase 
risk in finding tumors after transurethral resec-
tion and BCG treatment. Tumor size has also 
been used as a criteria to proceed with more ag-
gressive treatment in pT1-stage bladder cancer 
(23,24). Negative expression of this catenin has 
been related to worse prognosis, tumor stage, tu-
mor grade and UC disease recurrence in other 
studies (11,25). However, there were no studies 
of α-catenin expression in UUCs.
 Moderate γ-catenin expression was mar-
ginally significantly related to tumor recurrence 
(p = 0.071) in our study. The same result was 
described by Clairotte et al. in cases of bladder 
cancer. They classified CAM expression as either 
normal, heterogeneous or absent. The percent-
age of cases with absence of CAM expression 
was very low, as was in our series. They showed 
that heterogeneous expression of γ-catenin was 
related to worse prognosis and shorter disease-
free survival rate in patients with bladder can-
cer. If our moderate expression category is simi-
lar to their heterogeneous category, we observed 
similar findings in patients with UUCs (25).
 Some authors have discussed the accu-
racy of TMA immunohistochemistry in measur-
ing protein expression (26), but the advantages 
of the method outperform the disadvantages in 
terms of standardization of reaction and analysis 
and have been applied in the evaluation of many 
prognostic markers in different tumors including 
urothelial carcinoma for more than 20 years (27).
 We are aware that we have studied a 
small number of cases; however, UUCs are rare 
and it took a period of 10 years to collect the 
cases that were included in this study. A larger 
number of cases would allow analysis of differ-
ent aspects, such as tumor location. Tumor loca-
tion is important because it is well known that 
UCs of the renal pelvis and ureter have different 
behaviors. Additionally, it is difficult to compare 
different studies because each study establishes 
diverse criteria to evaluate immune expression 
of CAMs. A more standardized results evaluation 
would make it easier to discover the real role of 
CAMs in UCs.
 However, this is the first study to explore 
immune expression of components of the cad-
herin-catenin complex and their role in UUCs.
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